HeartBeam partners with Triple Ring to co-develop 3D vector ECG device; FDA submission targeted by Q4 2022

HeartBeam, Inc.

Five-phase expedited project includes device builds for verification, validation, packaging and manufacturing transfer.
Credit card-sized 3D vector ECG recorder via smartphone app; cloud-based diagnostic suggestion and 12-lead synthesis.
Targeting FDA 510(k) submission in Q4 2022; discussions with contract manufacturers underway.
Triple Ring brings medtech co-development expertise from early R&D through regulatory approval and commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.